Patent classifications
G01N2800/42
OMPA AND ASP14 IN VACCINE COMPOSITIONS AND AS DIAGNOSTIC TARGETS
Anaplasma phagocytophilum surface proteins Asp14 and OmpA and homologous genes from Anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the Anaplasmatacaea family. Asp14 and/or OmpA proteins or peptide fragments may be used in combination with other Anaplasmatacaea surface proteins to elicit an immune response. Furthermore, antibodies to Asp14 and/or OmpA proteins can be used in diagnostic methods to determine whether an individual has contracted an Anaplasmatacaea infection. Because of the conserved invasin domains in the surface proteins, a wide range of Anaplasmatacaea infections may be diagnosed, treated or prevented using compositions of the invention.
Compositions and methods relating to argininosucccinate synthetase
Processes and compositions for the therapeutic treatment of pathogenic Gram-negative bacterial infection are provided whereby arginino succinate synthetase or PEGylated arginino succinate synthetase is administered to a subject to inactivate endotoxin thereby reducing the likelihood of bacterial sepsis and improving patient outcome.
CHEMICAL AND BIOCHEMICAL ADDUCTS AS BIOMARKERS FOR ORGANOPHOSPHATE EXPOSURE
Provided are methods for identifying OP-adducted biomarkers of OP exposure as well as compounds containing OPs that can provide OP adducts and compounds of Formula 1 for eliciting antibodies that specifically and selectively bind to the OP adducts, wherein the Formula 1 compounds have the structure of OP-Peptide-Linker-CP, wherein CP is a carrier protein, OP represents a structure corresponding to that of a reactive organic phosphorous compound covalently modifying a tyrosine residue hydroxyl group of the peptide of Formula I and the other variable groups are as described herein.
PLATFORM AND METHOD FOR IDENTIFYING PAST EXPOSURE TO CHEMICAL AGENTS OR HEAVY METALS
A method for determining past exposure to chemical agents or heavy metals may include coating a capture material with a capture reagent. The capture reagent may be selected based on an ability of the capture reagent to bind with a target antibody, and the target antibody may be an indicator associated with a particular chemical agent or heavy metal. The method may further include interrogating a clinical sample associated with an individual by forming a mixture of the capture material and the clinical sample, and determining an exposure status of the individual to the particular chemical agent or heavy metal based on whether the capture material demonstrates capture of the indicator.
Chemical and biochemical adducts as biomarkers for organophosphate exposure
The present disclosure provides organophosphorous (OP) compounds of Formula (I), Formula (II) and Formula (III):
OP-Peptide-Linker-CP(I),
OP-Peptide-Linker(II); and ##STR00001## wherein OP is ##STR00002##
including that structure corresponding to a reactive organophosphorous reagent, nerve agent or pesticide, or a pesticide PS to PO metabolite; P is the S.sub.p or R.sub.p stereoisomer; X is oxygen, sulfur, selenium or imino; R and R are as described; Peptide is a sequence of amino acids containing a serine, threonine or tyrosine to which the OP is attached, wherein the total number of amino acids is between 7 and 41; Linker is an amino acid or is derived from another bifunctional reagent capable of covalently attaching an OP-peptide to a CP; and CP is a carrier protein used to display haptens for antibody generation. The disclosure also provides methods for generating monoclonal or polyclonal antibodies specific for an OP-Peptide of a compound of Formula (I) or Formula (II) that can be used to diagnose the presence, identity, and quantity of OP adducts.
3-phenoxybenzoic acid-glucuronic acid conjugate, and preparation method and use thereof
The present disclosure provides a 3-phenoxybenzoic acid-glucuronic acid conjugate, and a preparation method and use thereof, and belongs to the technical field of pesticide detection. Compared with 3-phenoxybenzoic acid, the 3-phenoxybenzoic acid-glucuronic acid conjugate provided by the present disclosure features structural stability, high specificity, long limit of detection, and high content in urine, and can better serve as a marker that identifies whether an organism is killed due to pyrethroid pesticide poisoning. Namely, the 3-phenoxybenzoic acid-glucuronic acid conjugate can detect whether a toxicant (pyrethroid pesticides) is taken antemortem or exposed postmortem, and has an excellent application prospect in pyrethroid pesticide detection. The present disclosure provides a preparation method of a 3-phenoxybenzoic acid-glucuronic acid conjugate. The preparation method provided by the present disclosure features high product yield, simple operation, wide raw material sources, low costs, and suitability for industrial production.